SFDA Tightens Heparin Control
This article was originally published in PharmAsia News
To further tighten the control on heparin quality, China's State FDA has posted a notice that requires, starting April 9, all heparin producers to test for impurities such as chondroitin sulphate in heparin sodium products, including raw materials and injections. Besides following current testing standards, the manufacturers now need to add SFDA-approved complementary testing methods and items for heparin sodium and its injections. The companies also have to inspect each batch of raw materials and factory exports. All provincial-level food and drug administration offices will enforce the new regulation and stop errant producers from operating. (Click here for more - Chinese Language)
You may also be interested in...
Several experts spoke with Scrip about their take on how the biopharmaceutical industry's efforts to respond to COVID-19 might help industry's image problem.
Pharma pays $50m up front to tap insitro’s in vitro modeling technology, partners with Sensyne Health in blood disorders. Lilly’s COVID-19 partner AbCellera teams with Kodiak in ophthalmology R&D.
Early Research Suggests Wearables Can Spot Early Signs Of COVID-19; Fitbit Receives $2.5m Army Award
A consortium of researchers, including Fitbit, are developing algorithms to spot COVID-19 before people become ill.